Stacy, Author at Buhlmann Diagnostics Corp

Author: Stacy

LabSense News Q3 2025 Edition

In this LabSense News Q3 2025 we're covering New Partnership-Worldwide Collaboration with QuidelOrtho, Technical News- CALEX® Updates & New Automation Video, Product Highlights- ACE kinetic Enzymatic Assay, Recent Events - ADLM, AMLI.
Continue Reading

Connect with BUHLMANN at AMLI 2025

At BUHLMANN Diagnostics Corp, we empower healthcare professionals with innovative diagnostic tools —led by our trusted Calprotectin portfolio—for confident clinical decisions. Explore the science behind our accuracy and discover our RUO Allergy and Neuroimmunology solutions.

Continue Reading

BUHLMANN Diagnostics Corp – New Collaboration with QuidelOrtho

BUHLMANN Diagnostic Corp – New Partner Channel Agreement with Roche Diagnostics.

Continue Reading

Visit BUHLMANN at DDW 2025

Product Highlights DDW 2025 Venue Buhlmann Team Product Highlights We offer a comprehensive gastroenterology testing portfolio, featuring a range of assays for fecal calprotectin (fCAL), pancreatic elastase, and therapeutic drug monitoring (TDM). Our fCAL testing lineup includes the FDA 510(k)-cleared BÜHLMANN fCAL® ELISA, BÜHLMANN fCAL® turbo, and CALEX® Cap, as well as the Research Use
Continue Reading

BÜHLMANN Laboratories AG Announces Worldwide Collaboration with Beckman Coulter for BÜHLMANN fCAL turbo and fPELA turbo Assays

Amherst NH, September 2024- BÜHLMANN Laboratories AG, a leading manufacturer of specialty, high-quality in-vitro diagnostic and research assays, is pleased to announce the collaboration with Beckman Coulter for a worldwide distribution of the BÜHLMANN fCAL® turbo assay & BÜHLMANN fPELA® turbo assay on their clinical chemistry analyzers (AU480, AU680, AU5800, and DxC 700 AU) with
Continue Reading

AMLI 2024 Recap for BUHLMANN Diagnostics Corp

Key Highlights BUHLMANN Diagnostics Corp proudly participated in the 37th Annual Meeting of the Association of Medical Laboratory Immunologists (AMLI) from August 16-19, 2024, in Nashville, Tennessee. This event was a significant platform for showcasing our latest advancements and contributions to medical laboratory immunology. AMLI 2024 Assay Offerings Our booth showcased a comprehensive immunology assay
Continue Reading

BUHLMANN Diagnostics Corp’s ADLM 2024 Recap

Key Highlights We are thrilled to share the highlights of our successful participation in the Association for Diagnostics and Laboratory Medicine (ADLM) 2024 Annual Meeting & Clinical Lab Expo, held from July 28 to August 1 in Chicago, IL. ADLM 2024 Assay Offerings Our booth showcased our extensive range of fecal calprotectin (fCAL) products, the
Continue Reading

BUHLMANN Diagnostics Corp – Collaboration with Beckman Coulter

BUHLMANN Diagnostic Corp – New Partner Channel Agreement with Roche Diagnostics.

Continue Reading

BUHLMANN Diagnostics Corp Recap from DDW 2024

Key Highlights BUHLMANN Diagnostics Corp is excited to share highlights from our participation at Digestive Disease Week (DDW) 2024,  held May 18-21 in Washington, D.C.  Here is a brief overview of our assays offerings and the innovative research we presented. DDW 2024 Assay Offerings At BUHLMANN,  we offer the broadest range of fecal calprotectin (fCAL)
Continue Reading

CALEX Cap Updates- Extended Stability, Training Video & CALEX Cap 4.0

BÜHLMANN fCAL® turbo + CALEX® Cap (K191718 & K232057): FDA 510(k) cleared. For in vitro Diagnostic Use. BÜHLMANN fPELA® turbo is FDA 510(k) Exempt. For in vitro Diagnostic Use. CALEX® Cap Updates CALEX Cap 4.0- Improved Total Laboratory Automation (TLA), or Block Automation & Seamless Integration TLA Compatibility: CALEX®Cap 4.0 integrates smoothly with TLA, enhancing workflow efficiency on
Continue Reading